Information Provided By: 
Fly News Breaks for March 30, 2017
ABMD
Mar 30, 2017 | 08:01 EDT
Leerink analyst Danielle Antalffy raised her price target for Abiomed to $150 from $140 to reflect recent multiple expansion across MedTech and the market more broadly. The analyst continues to believe Abiomed is tracking ahead of its long-term vision of over $1B in revenue from the current high risk PCI and cardiogenic shock indications alone by 2021. She reiterates an Outperform rating on the shares.
News For ABMD From the Last 2 Days
There are no results for your query ABMD
